Hester Biosciences

Hester Biosciences Ltd on Thursday reported a nearly three-fold jump in profit for the December quarter of 2024-25, mainly driven by foreign exchange gains. The company's profit after tax stood at Rs 11.41 crore in the October-December quarter of 2024-25 compared to Rs 4.02 crore in the year-ago period, an exchange filing said. Revenue from operations dropped by 6 per cent to Rs 63.22 crore for the third quarter of 2024-25 compared to Rs 66.98 crore in the year-ago period. The company recorded an unrealised foreign exchange gain of Rs 7.83 crore due to currency fluctuations. Revenue from animal healthcare division dropped 24 per cent while that from poultry segment rose by 12 per cent and from pet care more than doubled during the quarter. Rajiv Gandhi, CEO and MD of Hester Biosciences said, Looking ahead, our focus remains on achieving bottom-line targets while driving growth across divisions. The upcoming launch of the Avian Influenza vaccine, scheduled for release this year, is

Is now looking to add dermatology, nutrition, grooming, anti-infective and specialty products in this segment

The technology transfer from Bharat Biotech will enable Hester to provide the drug substance from August 2021 to BB for its vaccine production

The company said it has tied up with the Gujarat government to explore the production of Covid-19 vaccine through technology transfer from Bharat Biotech

Hester Biosciences on Sunday said it has tied up with the Gujarat government to explore the production of the Covid-19 vaccine through technology transfer from Bharat Biotech

Smaller players are bullish on playing crucial role in nation's vaccine infrastructure

With vaccines of some firms already in animal trial phase, developers say that if all goes well, India could have a vaccine by next year

The company's consolidated total revenue grew by 10.87 per cent to Rs 50.99 in Q3 of FY'20 as compared to Rs 45.99 crore in Q3 of FY'19

The stock dipped 7% to Rs 716, falling 9% from intra-day high on BSE.

The stock rallied 9% to Rs 777 after the company said that the board will meet on June 29 to consider to raise funds.

The stock has surged 19% to Rs 630 after posting 56% YoY growth in net profit at Rs 55 crore in Q4FY16

Net sales rise to Rs 28.18 cr for quarter under review as against Rs 23.36 cr in the year-ago period